SCHEDULE 13G/A: Biotechnology Value Fund Group Discloses 8.1% Passive Stake in iTeos Therapeutics

A group of investment entities led by Biotechnology Value Fund, L.P. has disclosed an 8.1% passive beneficial ownership stake in iTeos Therapeutics, Inc. as of March 31, 2025.

Summary

• Biotechnology Value Fund, L.P. and its affiliated entities (the "Reporting Persons") have filed an amended Schedule 13G regarding their beneficial ownership in iTeos Therapeutics, Inc.
• As of March 31, 2025, the Reporting Persons collectively beneficially owned 3,075,000 shares of iTeos Therapeutics, Inc. Common Stock.
• This aggregate ownership represents approximately 8.1% of the outstanding shares of iTeos Therapeutics, Inc.
• The percentage is calculated based on 38,194,341 shares outstanding as of February 28, 2025, as reported by iTeos Therapeutics, Inc. in its Annual Report on Form 10-K.
• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of ownership and does not contain performance or strategic updates from the issuer.

Positives

• A significant institutional investor, Biotechnology Value Fund, L.P. and its affiliates, holds a substantial 8.1% stake in iTeos Therapeutics, Inc., indicating a notable investment position.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional ownership stake provides transparency regarding the company's shareholder base and the passive nature of this investment.

Key Dates

Keywords

iTeos Therapeutics, Biotechnology Value Fund, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, Biotechnology, Pharmaceuticals